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ABSTRACT
Objectives To compare 1-year clinical efficacy of (1)
initial triple disease-modifying antirheumatic drug
therapy (iTDT) with initial methotrexate (MTX)
monotherapy (iMM) and (2) different glucocorticoid (GC)
bridging therapies: oral versus a single intramuscular
injection in early rheumatoid arthritis.
Methods In a single-blinded randomised clinical trial
patients were randomised into three arms: (A) iTDT
(methotrexate+sulfasalazine+hydroxychloroquine) with
GCs intramuscularly; (B) iTDT with an oral GC tapering
scheme and (C) MTX with oral GCs similar to B. Primary
outcomes were (1) area under the curve (AUC) of Health
Assessment Questionnaire (HAQ) and Disease Activity
Score (DAS) and (2) the proportion of patients with
radiographic progression.
Results 281 patients were randomly assigned to arms A
(n=91), B (n=93) or C (n=97). The AUC DAS and HAQ
were respectively −2.39 (95% CI −4.77 to −0.00) and
−1.67 (95% CI −3.35 to 0.02) lower in patients receiving
iTDT than in those receiving iMM. After 3 months,
treatment failure occurred less often in the iTDT group,
resulting in 40% fewer treatment intensifications. The
difference in treatment intensifications between the arms
required to maintain the predefined treatment goal
remained over time. No differences were seen between the
two GC bridging therapies. Respectively 21%, 24% and
23% of patients in arms A, B and C had radiographic
progression after 1 year. Patients receiving iTDT had more
adjustments of their medication owing to adverse events
than those receiving iMM.
Conclusions Treatment goals are attained more quickly
and maintained with fewer treatment intensifications with
iTDT than with iMM. However, no difference in radiographic
progression is seen. Both GC bridging therapies are equally
effective and, therefore, both can be used.
Trial registration number ISRCTN26791028.
INTRODUCTION
Recently EULAR updated the recommendations
for the management of rheumatoid arthritis (RA).1
In patients with newly diagnosed RA the
guidelines recommend that (1) the initial treatment
strategy should encompass methotrexate (MTX)
as monotherapy or in combination with other
disease-modifying antirheumatic drugs (DMARDs),
irrespective of glucocorticoids (GCs); (2) treatment
is targeted to achieve remission, or low disease
activity and (3) treatment should be adjusted if
there is no improvement after 3 months or the
target has not been reached by 6 months. When
poor prognostic factors are present, biological
agents should be considered if the initial treatment
strategy has failed, or otherwise one could switch
to a(nother) combination of DMARDs. Functional
and radiological outcomes improve if current
guidelines are upheld.1 2 Nevertheless, some major
points for debate still exist.
First, 2010 criteria for RA3 are more and more
often incorporated into daily practice. All current
guidelines, however, were formulated using data
from studies in patients fulfilling 1987 RA
criteria.1 4 5 Thus trials comparing initial treatment
strategies in the early phase of RA are needed for
validation.
Second, several clinical trials concluded that
initial combination therapy had better clinical effi-
cacy than monotherapy; however, most rheumatolo-
gists have not implemented this in daily practice.6–10
Moreover, current guidelines do not recommend
combination therapy for all patients with newly
diagnosed RA.1 4 The principal motive for disre-
garding combination therapy was because (1) trials
were biased by GCs, (2) patients were not DMARD
naïve and (3) there were concerns about safety.11 12
Third, GCs have a rapid anti-inflammatory effect
and are therefore used as bridging therapy to treat
active disease in between initiation of DMARD(s)
and the onset of their therapeutic effect.13 However,
trials specifically comparing GC bridging therapies
are sparse. More trials are, therefore, needed to
investigate optimal dosage and tapering schemes.
Therefore, our aim was to compare in patients
with very early RA the 1-year clinical efficacy of (1)
initial triple DMARD therapy (iTDT) with initial
MTX monotherapy (iMM), unbiased by GCs and
(2) different GC bridging therapies: oral versus a
single intramuscular injection.
PATIENTS AND METHODS
Patients
For this study, data were used from a clinical trial
(ISRCTN26791028)—namely, treatment in the
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Rotterdam Early Arthritis Cohort (tREACH).14 tREACH, a mul-
ticentre, stratified single-blinded trial, is carried out in eight
rheumatology centres in the Netherlands. Medical ethics com-
mittees at each participating centre approved the study protocol
and all patients gave written informed consent before inclusion.
Inclusion criteria for the tREACH are: age ≥18 years, arthritis in
one or more joint(s) and symptom duration <1 year. Exclusion
criteria for the tREACH are given in online supplement 1.
Patients were recruited from the outpatient clinics of all par-
ticipating centres between July 2007 and April 2011. Eligible
patients were stratified into three groups according to their like-
lihood of progressing to persistent arthritis based on the Visser
model.15 For this analysis we included the high probability
stratum (>70% probability of developing persistent arthritis).
Randomisation and blinding
Patients were randomised, using variable block randomisation
stratified for centre, by an independent call-centre. Trained
research nurses, blinded to the allocated treatment arm through-
out the study, examined patients and calculated the Disease
Activity Score (DAS).
Design
Patients were randomised into three groups
A. iTDT (MTX, sulfasalazine and hydroxychloroquine) with
GCs intramuscularly;
B. iTDTwith an oral GC tapering scheme;
C. iMM with oral GCs similar to B.
Concurrent treatment with non-steroidal anti-inflammatory
drugs and intra-articular GC injections (maximum of two per
3 months) was allowed.
DMARD dosages were: MTX 25 mg/week orally (dosage
reached after 3 weeks), sulfasalazine 2 g/day and hydroxychloro-
quine 400 mg/day (reduced to 200 mg/day after 3 months). GCs
were given either intramuscularly (methylprednisolone 120 mg
or triamcinolone 80 mg) or in an oral tapering scheme (weeks
1–4: 15 mg/day, weeks 5–6: 10 mg/day, weeks 7–8: 5 mg/day
and weeks 9–10: 2.5 mg/day). All patients received folic acid
(10 mg/week) during MTX prescription. Osteoporosis prophy-
laxis (risedronate 35 mg/week and calcium/vitamin D combin-
ation 500/400 mg/IU/day) was given to patients in treatment
arms B and C, during the first 3 months.
A treat-to-target approach was used, aiming for a DAS
<2.4.16 If DAS was ≥2.4 medication was intensified.
Intensification steps were in the order (1) MTX+etanercept
(50 mg/week, subcutaneously), (2) MTX+adalimumab (40 mg/
2 weeks, subcutaneously) and (3) MTX+abatacept (500–
1000 mg/4 weeks, intravenously, depending on weight).
Treatment intensifications were the same for each treatment
arm.
If DAS was <1.6 at two consecutive visits, medication was
tapered. Hierarchically ordered tapering steps were: (1) bio-
logical agent, (2) sulfasalazine, (3) MTX and (4) hydroxychoro-
quine. Biological agent(s), MTX and sulfasalazine were
gradually discontinued, whereas hydroxychloroquine was
stopped immediately. A flare during tapering, defined as DAS
≥2.4, resulted in restarting full treatment, according to the stage
in the protocol.
Outcomes and assessments
Patients were examined every 3 months for all outcomes, except
for hand/foot radiographs, which were obtained at baseline and
half-yearly.
Primary outcomes were (1) area under the curve (AUC)
Health Assessment Questionnaire (HAQ) and DAS and (2) pro-
portion of patients with radiographic progression. Secondary
endpoints were disease activity (state), functional ability, EULAR
response criteria,17 Boolean-defined remission criteria,18 self-
assessed disease activity and medication usage over time and
after 12 months of treatment.
DAS and its thresholds are used for disease state categorisa-
tions.16 Functional ability is measured with the HAQ.19 Higher
HAQ scores indicate poorer function. Radiographic progression
was measured with the modified Sharp–van der Heijde score
(SHS).20 Radiographs were read chronologically by two out of
five qualified assessors, who were blinded to the patient’s iden-
tity and treatment allocation.21 Mean SHS are reported.22
Weighted κ between assessors was 0.36 with 98% agreement.
The proportion of patients with radiographic progression,
defined as SHS change >0.5 and >1.2 (the smallest detectable
change) and >1.2 a year, was also calculated.22
EULAR response criteria are based on attained level and
change in DAS (see online supplement 2).17 Boolean remission
criteria are defined as having a tender joint count, swollen joint
count, C-reactive protein (in mg/dL) and patient global assess-
ment (0–10 scale) of ≤1.18 Self-assessed disease activity is mea-
sured with the RA Disease Activity Index questionnaire
(RADAI).23 Higher RADAI scores indicate more active disease.
Safety monitoring and toxicity
Safety monitoring occurred according to Dutch guidelines,24 25
which included laboratory tests at fixed intervals. Study medication
was either stopped or the dosage lowered in accordance with the
protocol if (serious) adverse events14 were seen by the attending
rheumatologist. MTX could be given subcutaneously if patients
had gastrointestinal complaints. If MTX had to be stopped for
safety reasons, leflunomide (20 mg/day) was substituted.14
Statistical analysis
Sample-size calculation was based upon AUC HAQ, using data
from the BeSt study,7 where mean AUC HAQ of combination
therapy and monotherapy respectively were 7.7 (SD 5.5) and
10.5 (SD 7.4). A target sample size of 270 patients per probabil-
ity stratum and thus 90 patients per arm, was needed to detect
the mentioned difference with a power of 80% and two-sided
α=0.05. This size is sufficient to detect a difference of 6.1 AUC
DAS and 20% difference in radiographic progression.14
Clinical efficacy was calculated in an modified
intention-to-treat (mITT) and per-protocol analysis. In mITT
analyses patients are analysed in the groups to which they were
randomised, regardless of whether they received or adhered to
the allocated intervention. For the primary, but not the second-
ary, outcomes missing values are imputed. Statistical comparison
of the baseline characteristics and outcomes (after 12 months)
between iTDT and iMM (arms B vs C) and both GC bridging
therapies (arms A vs B) were made by Student t test, χ2 test or
Wilcoxon rank-sum test, as appropriate.
We used the AUC to compare DAS and HAQ over time
between treatment arms, in which missing values at each time-
point were substituted with the mean value of the correspond-
ing treatment arm. Radiographic progression was extrapolated
or interpolated if the SHS was missing after 12 months.
We also performed adjusted analyses for our primary out-
comes, in which we corrected for baseline imbalances, rheuma-
toid factor, anti-citrullinated protein/peptide antibodies and
baseline HAQ, DAS or SHS, as appropriate, using multivariate
analyses.
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Figure 1 Trial profile and protocol violations. Results are shown as number (%). 1Other reasons are: 3× no compliance, 1× pregnancy wish and
1× continuation of SASP after switch to etanercept. The figure shows the flowchart of the tREACH trial, whereas the table shows the protocol
violations within the tREACH trial during the first year of follow-up. Other reasons for dropping out, in the flowchart, were incorrect randomisation
and problems with communication. GCs, glucocorticoids; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate; SASP, sulfasalazine;
tREACH, treatment in the Rotterdam Early Arthritis Cohort.
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All analyses were performed for patients in the high-
probability stratum and two subgroups consisting of patients
with RA according to 1987 and 2010 criteria.3 5 All statistical
analyses were carried out using STATAV.12.0. A p value <0.05
was considered statistically significant.
RESULTS
Patients
A total of 797 patients were assessed for eligibility and of those,
568 were included. In the high-probability stratum 281 patients
were randomly assigned to treatment arm A (n=91), B (n=93)
or C (n=97) (figure 1). Besides an mITT analysis, we also per-
formed a per-protocol analysis. We excluded, from our per-
protocol analysis, respectively 32 (35%), 37 (40%) and 32
(33%) patients randomised to arms A, B and C (figure 1).
At baseline, the symptom duration and patients fulfilling 1987
criteria for RA differed significantly between arms (table 1).
Clinical outcome
The difference in AUC DAS between iTDTand iMM was −2.39
(95% CI −4.77 to −0.00, p=0.0497), and −0.91 (95% CI
−3.17 to 1.34, p=0.42) between both GC bridging therapies.
Adjusted differences were respectively −2.61 (95% CI −4.55 to
−0.66, p=0.009) and −0.015 (95% CI −1.96 to 1.99, p=0.99).
The largest difference in disease activity (states) between treat-
ment arms was seen after 3 months, after which it gradually
diminished (figure 2). After 12 months DAS was 0.08 (95% CI
−0.34 to 0.19) lower in patients with iTDT than in those with
iMM. Difference in DAS between the different GC bridging
therapies was −0.20 (95% CI −0.45 to 0.04). Similar results
were found in our multivariate analyses (data not shown). No
differences in disease activity states were found after 12 months
between iTDT and iMM, or between the two GC bridging ther-
apies (table 2). DAS and its components over time per treatment
arm are given in online supplement 4.
There was no significant difference in SHS after 12 months of
treatment (table 2). Respectively 21%, 24% and 23% of patients
in arms A, B and C had radiographic progression. The cumula-
tive probability plots for the three treatment arms were superim-
posable (see online supplement 3).
Functional improvement was seen in all patients. Difference in
AUC HAQ between iTDT and iMM was −1.67 (95% CI −3.35
to 0.02, p=0.052), and −0.46 (95% CI −2.04 to 1.12, p=0.57)
between both GC bridging therapies (figure 2). Adjusted differ-
ences were, respectively, −1.30 (95% CI −2.45 to −0.14,
p=0.028) and 0.33 (95% CI −0.84 to 1.51, p=0.58). No signifi-
cant difference in functional ability was seen after 12 months
(table 2). Secondary endpoints are shown in table 2 and figure 2.
We also performed a per-protocol analysis, which showed
similar results (data not shown). The above-mentioned analyses
were performed in both subgroups, and produced similar results
(see online supplement 5 and 6).
Table 1 Baseline characteristics and clinical response after 12 months for each induction therapy group, according to intention-to-treat
Characteristics A. MTX+SASP+HCQ+IM GCs (n=91) B. MTX+SASP+HCQ+oral GCs (n=93) C. MTX+oral GCs (n=97)
Demographic
Age (years), mean (SD) 53 (15) 54 (14) 54 (14)
Sex, female, n (%) 55 (60) 67 (72) 68 (70)
Disease characteristics
Symptom duration (days), mean (SD)* 162 (98) 184 (92) 154 (83)
ACPA positive, n (%) 74 (81) 67 (72) 75 (77)
RF positive, n (%) 69 (76) 65 (70) 65 (67)
Fulfilment of RA criteria, n (%)
1987† 69 (76) 57 (61) 63 (65)
2010 87 (96) 88 (95) 95 (98)
Disease activity
DAS, mean (SD) 3.28 (0.82) 3.40 (1.07) 3.38 (0.97)
TJC44, median (IQR) 8 (4–14) 9 (5–15) 10 (4–14)
SJC44, median (IQR) 8 (5–12) 7 (4–12) 7 (4–12)
General health, median (IQR)‡ 52 (34–70) 55 (29–69) 53 (38–70)
ESR in mm/h, median (IQR) 27 (14–40) 22 (13–40) 24 (14–42)
CRP in mg/L, median (IQR) 8 (3.5–23) 6.5 (4.5–19) 11 (5–26)
Radiographs (hand/foot)
Total SHS (0–488), median (IQR) 0.5 (0–2) 0.5 (0–2) 1 (0–2.5)
Erosion score (0–280), median (IQR) 0 (0–1) 0 (0–1) 0.5 (0–1)
JSN score (0–168), median (IQR) 0 (0–1) 0 (0–1) 0 (0–1.5)
Erosive disease, n (%)§ 10 (11) 6 (6) 8 (8)
Patient-reported outcomes¶
HAQ, mean (SD) 0.98 (0.67) (n=84) 0.96 (0.64) (n=86) 1.06 (0.68) (n=92)
RADAI (0–10), mean (SD) 3.97 (1.83) (n=81) 3.94 (1.61) (n=82) 4.21 (1.82) (n=87)
*p=0.018 for B versus C.
†p=0.034 for A versus B.
‡General health is measured with a Visual Analogue Scale from 0 to 100 mm.
§Erosive disease is defined as having an erosion score >1 in three separate joints.36
¶Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI.
ACPA, anti-citrullinated protein/peptide antibodies; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HAQ, Health
Assessment Questionnaire; HCQ, hydroxychloroquine; IM, intramuscular; JSN, joint space narrowing; MTX, methotrexate; RA, rheumatoid arthritis; RADAI, RA Disease Activity Index
questionnaire; RF, rheumatoid factor; SASP, sulfasalazine; SHS, modified Sharp–Van der Heijde score; SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints).
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Medication
After 3 months 40% fewer biological agents were prescribed in
the iTDT group than in the iMM group. This difference
remained over time (figure 3). After 12 months, respectively
27% and 43% of patients, receiving iTDTand iMM, were using
a biological agent (p=0.03). Moreover, for more patients
receiving iMM their first biological agent had failed (16% vs
6%, p=0.03) (figure 3). In 117/281 (42%) of patients treatment
could be tapered at one or more time points, and of those, 14/
117 (12%) flared. Treatment could be tapered in all treatment
arms, without differences in flare rates (figure 3). Biological
usage did not differ between the two GC bridging therapies
(figure 3). This analysis was also performed in both subgroups
and showed similar results (see online supplements 5 and 6).
Adverse events (AEs)
No differences in serious AEs were seen (table 3). However, the
proportion of patients with medication adjustments due to AEs
differed significantly between iTDT and iMM (60/93 (65%) and
44/97 (45%), p=0.008). Besides switching to MTX subcutane-
ously, these differences vanished after stratification for drug
(table 3). No differences were seen between the two GC bridg-
ing therapies. Most treatment adjustments occurred in the first
3 months (51/159, 32%). Among all patients gastrointestinal
complaints and fatigue were the most commonly reported AEs,
respectively 56% and 36% (table 3).
DISCUSSION
In this study, unbiased for GCs, we showed that the AUC DAS was
significantly less in the iTDT group than in the iMM group. A
trend was observed for the AUC HAQ. Treatment goals were
attained more quickly and maintained with 40% fewer treatment
intensifications in the iTDT group. Moreover, for more patients
receiving iMM their first biological agent had failed, reducing
therapeutic options. Disease activity, functional ability and radio-
graphic progression, after 12 months, did not differ between
Figure 2 (Self-assessed) disease activity, functional ability and radiographic joint damage over time, stratified for induction therapy. Error bars
indicate respectively 95% CIs and IQR for given means and median. DAS, Disease Activity Score; GCs, glucocorticoids; HAQ, Health Assessment
Questionnaire; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease Activity Index questionnaire;
SASP, sulfasalazine; SHS, modified Sharp–Van der Heijde score.
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iTDT and iMM. No differences in serious AEs were seen.
However, patients receiving iTDT had more medication adjust-
ments due to AEs than the iMM group. Treatment could be
tapered in all treatment arms, without differences in flare rates. No
differences were seen between the two GC bridging therapies.
We were able to analyse the difference in efficacy between
iTDT and iMM, unbiased for GCs and in DMARD-naïve
patients. We found no difference in disease activity, functional
ability and radiographic progression after 12 months of
treatment, owing to our treat-to-target approach (intensifying
treatment until the target is reached). Therefore, it is not the
endpoint, but progress towards the endpoint which
matters most. Aletaha et al26 have shown that the initial
clinical response is related to long-term disease activity and,
indirectly, the level of joint destruction and treatment changes
needed to achieve the predefined treatment goals. With iTDT,
treatment goals were attained more quickly, resulting in fewer
treatment alterations, including the prescription of 40% fewer
biological agents. However, no differences in radiographic pro-
gression were seen, which was probably owing to early initiation
of intensive treatment, resulting in less joint destruction and
thus less radiological progression. Moreover, the early initiation
of biological agents in the iMM group might have prevented/
delayed the radiographic progression.
In our trial switching to biological agents was possible after
3 months, if the target had not been reached. In the iMM group
one might argue that triple DMARD therapy rather than bio-
logical agents should be the first step-up, especially since there is
no evidence that step-up to a biological agent rather than triple
DMARD therapy results in better clinical efficacy.10 27 28
Moreover, the updated EULAR guidelines only recommend
switching to biological agents after 3 months if (1) there is no
improvement in disease activity and (2) poor prognostic factors
are present (ie, autoantibody positivity and erosive disease).1
Twenty of the 36 (56%) patients for whom iMM treatment had
failed after 3 months were EULAR non-responders, defined as
Table 2 Clinical response for each induction therapy group, according to intention-to-treat
Clinical response A. MTX+SASP+HCQ+IM GCs (n=77) B. MTX+SASP+HCQ+oral GCs (n=84) C. MTX+oral GCs (n=87)
Disease activity
AUC DAS, mean (SD)* 22.32 (7.16) (n=91) 23.24 (8.31) (n=93) 25.63 (8.37) (n=97)
DAS, mean (SD) 1.40 (0.68) 1.61 (0.87) 1.68 (0.89)
TJC44, median (IQR) 0 (0–2) 0 (0–4) 1 (0–4)
SJC44, median (IQR)† 0 (0–2) 0 (0–1) 0 (0–2)
General health, median (IQR)‡ 18 (8–32) 22,5 (9.5–37.5) 23 (10–40)
ESR in mm/h, median (IQR) 11 (5–18) 10,5 (6.5–20.5) 12 (6–21)
CRP in mg/L, median (IQR) 3 (1–5.2) 4 (1–7) 3 (1.9–5)
ΔDAS (T12–T0), mean (SD) −1.83 (−1.03) −1.75 (−1.14) −1.69 (−1.27)
Disease state according to DAS, n (%)
Moderate to high disease activity (DAS ≥2.4) 8 (10) 15 (18) 19 (22)
Low disease activity (1.6≥ DAS <2.4) 22 (29) 24 (29) 24 (28)
Remission (DAS <1.6) 47 (61) 45 (54) 44 (51)
Boolean remission criteria, n (%)§ 17 (22) 13 (16) 14 (16)
EULAR response criteria (T12–T0), n (%)¶
Good 54 (70) 52 (62) 57 (66)
Moderate 13 (17) 19 (23) 9 (10)
None 10 (13) 13 (15) 21 (24)
Radiographs (hand/foot)
Total SHS (0–488), median (IQR) 1 (0–3) 1 (0–3) 1 (0–3.5)
Erosion score (0–280), median (IQR) 0.5 (0–1.25) 0.5 (0–1.5) 0.5 (0–1.5)
JSN score (0–168), median (IQR) 0.5 (0–1.5) 0 (0–1.5) 0.5 (0–1.5)
ΔTotal SHS (T12–T0), median (IQR) 0.13 (0–1) 0 (0–1) 0 (0–1)
Patients with progression >0.5, n (%) 25 (33) 24 (29) 28 (33)
Patients with progression >1.2, n (%) 16 (21) 20 (24) 19 (23)
Erosive disease, n (%)** 8 (10) 19 (23) 15 (17)
Patient-reported outcomes††
AUC HAQ, mean (SD) 6.46 (4.96) (n=84) 6.92 (5.43) (n=86) 8.59 (5.90) (n=92)
HAQ, mean (SD) 0.38 (0.46) (n=69) 0.51 (0.55) (n=78) 0.63 (0.57) (n=82)
ΔHAQ (T12–T0), mean (SD) −0.48 (−0.63) (n=65) −0.42 (−0.59) (n=74) −0.47 (−0.53) (n=80)
RADAI (0–10), mean (SD) 1.43 (1.24) (n=68) 1.78 (1.52) (n=75) 2.15 (1.81) (n=79)
ΔRADAI (T12–T0), mean (SD) −2.22 (−1.68) (n=63) −2.06 (−1.87) (n=69) −2.11 (−1.91) (n=74)
*p=0.0497 for B versus C.
†p=0.022 for B versus C.
‡General health is measured with a Visual Analogue Scale from 0 to 100 mm.
§Boolean remission criteria are defined as having a TJC44 ≤1, SJC44 ≤1, VAS global ≤10 mm and CRP ≤10 mg/L.
¶EULAR response criteria are based on attained level and change in DAS.
**Erosive disease is defined as having an erosion score >1 in three separate joints.36
††Not everyone filled in a (complete) questionnaire and therefore n is different for HAQ and RADAI.
AUC, area under the curve; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; GCs, glucocorticoids; HAQ, Health Assessment Questionnaire; HCQ,
hydroxychloroquine; IM, intramuscular; JSN, joint space narrowing; MTX, methotrexate; RADAI, Rheumatoid Arthritis Disease Activity Index questionnaire; SASP, sulfasalazine; SHS,
modified Sharp–Van der Heijde score; SJC44, swollen joint count (44 joints); TJC44, tender joint count (44 joints); VAS, visual analogue scale.
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having a DAS >2.4 and <0.6 decline in DAS from baseline,
with poor prognostic factors. Therefore, we think intensification
to biological agents after iMM treatment had failed was
reasonable.
For economic reasons efficient use of biological agents is
needed to be able to continue optimal rheumatic care in the
future.29 With iTDT treatment, goals are attained more quickly
and maintained with 40% fewer biological agents, reducing
costs enormously. Better disease control improves worker prod-
uctivity, and thus costs due to loss of productivity are also
reduced.30 31 However, the cost–utility analysis of the tREACH
trial still has to reconfirm this statement.
Patients and/or rheumatologists, however, may be averse to
iTDT treatment, mainly because of the large amount of drugs
that have to be taken. Medication adherence in RA is strongly
influenced by a patient’s belief about the need for the drugs.32
These beliefs are moulded by rheumatologists through the infor-
mation given about the disease and treatment approach.32 A
personalised medicine approach would be ideal in this very
early phase, especially since 60% respond well to iMM; con-
versely, therefore, some patients receiving iTDT are overtreated.
Determination of early GC response after treatment initiation is
a promising predictor, possibly leading to a more personalised
medicine approach.33 Therefore, we think that future research
should focus on developing a more personalised treatment
approach, in which differentiation between patients who would
thrive on iMM and those who need iTDT might be a first step.
In 42% of patients treatment could be tapered, and of those,
12% flared. Therefore, we think tapering DMARDs and/or bio-
logical agents is justified in patients with sustained remission.
However, patients should still be monitored strictly during
tapering. Data on tapering medication are sparse, especially in
early RA.1 34 Future research is needed to determine (1) when
to start tapering, (2) how to taper and (3) the optimal interval
between taperings.
We found that intramuscular and oral GCs are equally effect-
ive as bridging therapy, but one single injection might be more
feasible. However, duration of our GC tapering scheme was
short (10 weeks) and the initial dosage was low (15 mg) in com-
parison with, for example, the COBRA regimen (respectively
28 weeks and 60 mg).9 Because GCs have disease-modifying
traits with longlasting benefits even after withdrawal, a different
GC oral tapering scheme might be superior.13 However, if we
compare our iMM treatment with the COBRA-light strategy,
intensification to biological agents after 6 months is equally indi-
cated (respectively 36% and 41%).35 In the COBRA-light trial,
however, the treatment goal is remission instead of low disease
activity, which prevents useful direct comparison.35 Therefore,
future research is needed for optimising GC bridging therapies.
Our study had certain limitations. Foremost, baseline imbal-
ances occurred, despite randomisation, which is why we also
performed an adjusted analysis. After adjustment similar results
were found for the primary outcomes, but the difference in
AUC HAQ became significant (favouring iTDT). Additionally,
only research nurses, who assessed the DAS, were blinded to the
allocated treatment arm. This design was chosen, since we
wanted to mimic daily practice as far as possible. Single blind-
ing, however, might be a potential source of bias, because of the
aversion for iTDT by rheumatologists and/or patients (favouring
iMM) or (un)intentional misinformation due to the
Figure 3 Withdrawal, flares and medication usage over time and after 12 months, stratified for induction therapy. Results are shown as number
(%) unless stated otherwise. 1Other biological agents are: infliximab (A) and rituximab (B). 2Treatment could be tapered after 6 months. Therefore
the total amount of possible taperings is the sum of all assessments at the last three visits per treatment arm. 3A flare is defined as a Disease
Activity Score ≥2.4. The proportion is calculated by dividing the number of flares by the total number of taperings. *p=0.011 for B versus
C. †p=0.031 for B versus C. ‡p=0.028 for A versus B. GCs, glucocorticoids; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate; SASP,
sulfasalazine.
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rheumatologist’s beliefs (favouring iTDT). Moreover, for various
reasons 101 (36%) patients were excluded from our per-protocol
analysis, which was more than expected. Our exclusion percent-
age, however, was comparable with that of other trials.9–10 27
In conclusion, in our treat-to-target design, treatment goals
were attained more quickly and maintained with fewer treat-
ment intensifications, with iTDT than with iMM. However, no
difference was seen in radiographic progression. Before choos-
ing the initial treatment strategy, rheumatologists should be
aware of the benefits and risks, but additionally, known prog-
nostic factors and the patient’s wish should be taken into
account. One single intramuscular GC injection and a low-dose
oral GC tapering scheme would be sufficient as bridging
therapy.
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